[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-216944-en":3,"doc-seo-216944-105":29,"detail-sidebar-cat-0-en-105":89},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":4,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":20,"language":21,"language_code":22,"site_id":23,"html_lang":22,"table_of_contents":24,"faqs":25,"seo_title":26,"seo_description":14,"update_tm":27,"read_time":28},216944,687207412472,"Angel","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",7,"Healthcare","AHP Meclizine Hydrochloride Tablets Recall Notice","The Board of Pharmacy issues a product recall notice for AHP Meclizine Hydrochloride Tablets, USP (12.5 mg, 50 UD), at the retail level. American Health Packaging initiates the recall for lot 1024852 due to a drying loss result that falls outside specifications in the repackaged configuration. Although the measured loss-on-drying value is 5.3%, available data supports product stability, performance, and chemical integrity, indicating no meaningful risk to patient safety or therapeutic effectiveness. Meclizine tablets are used to treat vertigo associated with vestibular system diseases in adults.","The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.  \nAmerican Health Packaging, [Inc. is](Inc. is) initiating a drug recall to the RETAIL LEVEL for AHP Meclizine Hydrochloride Tablets, USP, 12.5 mg, 50 UD; Carton NDC\\#: 60687-775-65,(Individual Dose NDC\\#: 60687-775-11), for the lot listed below.  \nThis recall is being initiated due to a loss on drying out-of-specification result for Meclizine Hydrochloride Tablets, USP in the American Health Packaging repackaged configuration.  \nMeclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.  \nThe isolated loss-on-drying value of 5.3% does not present a meaningful risk to patient safety or therapeutic effectiveness, as product stability, performance, and chemical integrity remain supported by available data.  \nPRODUCT: AHP Meclizine Hydrochloride Tablets, USP, 12.5 mg, 50 UD  \nNDC NUMBER: Carton NDC\\#: 60687-775-65 (Individual Dose NDC\\#: 60687-775-11)  \nAHP LOT NUMBER: 1024852  \nEXPIRY DATE: 09/30/2026  \nSHIP DATES OF PRODUCT: 07/29/2025 to 09/16/2025","cbCaikmSu53dkbd6","https://ap.wps.com/l/cbCaikmSu53dkbd6","pdf",61458,1,"English","en",105,"# Recall notice details\n## Product and identifiers\n## Reason for recall\n## Patient safety assessment\n## Key dates","[{\"question\":\"What product is being recalled?\",\"answer\":\"AHP Meclizine Hydrochloride Tablets, USP, 12.5 mg, 50 UD (retail level). The notice lists Carton NDC 60687-775-65 and Individual Dose NDC 60687-775-11.\"},{\"question\":\"Why is the recall being initiated?\",\"answer\":\"The recall is initiated due to a loss on drying out-of-specification result for Meclizine Hydrochloride Tablets in the American Health Packaging repackaged configuration.\"},{\"question\":\"Does the recall indicate a meaningful safety risk to patients?\",\"answer\":\"No. The isolated loss-on-drying value of 5.3% is stated to not present a meaningful risk to patient safety or therapeutic effectiveness because stability, performance, and chemical integrity remain supported by available data.\"}]","AHP Meclizine Hydrochloride Tablets Recall Notice | PDF",1788828518,3,{"code":4,"msg":30,"data":31},"ok",{"site_id":23,"language":22,"slug":32,"title":13,"keywords":33,"description":14,"schema_data":34,"social_meta":84,"head_meta":86,"extra_data":88,"updated_unix":27},"ahp-meclizine-hydrochloride-tablets-recall-notice","",{"@graph":35,"@context":83},[36,52,66],{"@type":37,"itemListElement":38},"BreadcrumbList",[39,43,47,49],{"item":40,"name":41,"@type":42,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":44,"name":45,"@type":42,"position":46},"https://docshare.wps.com/document/","Document",2,{"item":48,"name":12,"@type":42,"position":28},"https://docshare.wps.com/document/healthcare/",{"item":50,"name":13,"@type":42,"position":51},"https://docshare.wps.com/document/ahp-meclizine-hydrochloride-tablets-recall-notice/216944/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"inLanguage":22,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":40,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-09-08",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79],{"name":70,"@type":71,"acceptedAnswer":72},"What product is being recalled?","Question",{"text":73,"@type":74},"AHP Meclizine Hydrochloride Tablets, USP, 12.5 mg, 50 UD (retail level). The notice lists Carton NDC 60687-775-65 and Individual Dose NDC 60687-775-11.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"Why is the recall being initiated?",{"text":78,"@type":74},"The recall is initiated due to a loss on drying out-of-specification result for Meclizine Hydrochloride Tablets in the American Health Packaging repackaged configuration.",{"name":80,"@type":71,"acceptedAnswer":81},"Does the recall indicate a meaningful safety risk to patients?",{"text":82,"@type":74},"No. The isolated loss-on-drying value of 5.3% is stated to not present a meaningful risk to patient safety or therapeutic effectiveness because stability, performance, and chemical integrity remain supported by available data.","https://schema.org",{"og:url":50,"og:type":85,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":87,"canonical":50},"index,follow",{"doc_id":7,"site_id":23},{"code":4,"msg":5,"data":90},[91,95,99,103,108,113,116,121,126,129,133],{"id":20,"doc_module":4,"doc_module_name":45,"category_name":92,"show_sort_weight":93,"slug":94},"Story & Novel",90,"story-novel",{"id":46,"doc_module":4,"doc_module_name":45,"category_name":96,"show_sort_weight":97,"slug":98},"Literature",80,"literature",{"id":51,"doc_module":4,"doc_module_name":45,"category_name":100,"show_sort_weight":101,"slug":102},"Exam",70,"exam",{"id":104,"doc_module":4,"doc_module_name":45,"category_name":105,"show_sort_weight":106,"slug":107},5,"Comic",60,"comic",{"id":109,"doc_module":4,"doc_module_name":45,"category_name":110,"show_sort_weight":111,"slug":112},6,"Technology",50,"technology",{"id":11,"doc_module":4,"doc_module_name":45,"category_name":12,"show_sort_weight":114,"slug":115},40,"healthcare",{"id":117,"doc_module":4,"doc_module_name":45,"category_name":118,"show_sort_weight":119,"slug":120},8,"Research & Report",30,"research-report",{"id":122,"doc_module":4,"doc_module_name":45,"category_name":123,"show_sort_weight":124,"slug":125},9,"Religion & Spirituality",20,"religion-spirituality",{"id":124,"doc_module":4,"doc_module_name":45,"category_name":127,"show_sort_weight":124,"slug":128},"World Cup","world-cup",{"id":130,"doc_module":4,"doc_module_name":45,"category_name":131,"show_sort_weight":130,"slug":132},10,"Lifestyle","lifestyle",{"id":134,"doc_module":4,"doc_module_name":45,"category_name":135,"show_sort_weight":104,"slug":136},19,"General","general"]